Literature DB >> 7888529

Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City.

B P Currie1, A Casadevall.   

Abstract

Cryptococcal infections are not reportable illnesses, and there have been limited attempts to estimate their incidence or prevalence. This study estimates the prevalence of cryptococcal disease in New York City in 1991 among human immunodeficiency virus (HIV)-infected patients who were at risk. Numerator data were generated by surveying all hospitals in New York City to determine the number of patients with cultures positive for Cryptococcus neoformans as well as the number of patients with positive cryptococcal latex agglutination tests in 1991; 517 culture-positive patients were identified, and 1,277 patients were estimated to have a positive cryptococcal latex antigen test. Of these cases, 96% were estimated to be related to infection with HIV. Denominator data were generated via an active surveillance program of the New York City Department of Health. The annual prevalence of cryptococcosis among HIV-infected patients at risk in New York City is estimated to be 6.1%-8.5%.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7888529     DOI: 10.1093/clinids/19.6.1029

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  81 in total

Review 1.  Host-pathogen interactions: basic concepts of microbial commensalism, colonization, infection, and disease.

Authors:  A Casadevall; L A Pirofski
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

2.  Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure.

Authors:  S P Franzot; J S Hamdan; B P Currie; A Casadevall
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

3.  Inositol acylation of glycosylphosphatidylinositols in the pathogenic fungus Cryptococcus neoformans and the model yeast Saccharomyces cerevisiae.

Authors:  S P Franzot; T L Doering
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

4.  Cryptococcal Meningitis in HIV-Infected Patients.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

5.  Purification and characterization of a 43-kilodalton extracellular serine proteinase from Cryptococcus neoformans.

Authors:  Jae il Yoo Ji; Yeong Seon Lee; Chul-Yong Song; Bong Su Kim
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

6.  Melanin, melanin "ghosts," and melanin composition in Cryptococcus neoformans.

Authors:  Y Wang; P Aisen; A Casadevall
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

7.  Serotyping of Cryptococcus neoformans strains isolated from clinical specimens in Thailand and their susceptibility to various antifungal agents.

Authors:  N Poonwan; Y Mikami; S Poosuwan; J Boon-Long; N Mekha; M Kusum; K Yazawa; R Tanaka; K Nishimura; K Konyama
Journal:  Eur J Epidemiol       Date:  1997-04       Impact factor: 8.082

8.  Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection.

Authors:  Kirsten Nielsen; Gary M Cox; Anastasia P Litvintseva; Eleftherios Mylonakis; Stephanie D Malliaris; Daniel K Benjamin; Steven S Giles; Thomas G Mitchell; Arturo Casadevall; John R Perfect; Joseph Heitman
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

9.  Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.

Authors:  Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

10.  Human cryptococcosis: relationship of environmental and clinical strains of Cryptococcus neoformans var. neoformans from urban and rural areas.

Authors:  A C N Delgado; H Taguchi; Y Mikami; M Myiajy; M C B Villares; M L Moretti
Journal:  Mycopathologia       Date:  2005-01       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.